The US Food and Drug Administration on Thursday revised the emergency use authorization for Evusheld, a monoclonal antibody against Covid-19 for immunocompromised people and those who cannot be vaccinated for medical reasons, to double the initial dose. People who’ve already received the drug should go back for an additional dose as soon as possible, the agency said.

(SOURCE) https://www.cnn.com/2022/02/27/health/fda-evusheld-double-initial-dose/index.html